Foxin

Quick links to important sections

Foxin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Foxin

Quick Facts

Property Description
Active ingredient Fexofenadine Hydrochloride
Form Oral tablet, Oral suspension
Pharmacological class Second-generation H₁-receptor antagonist
Common use Allergy relief
Origin Synthetic Piperidine derivative

What Type of Antihistamine is Foxin?

Foxin is an antihistamine medication whose active substance is Fexofenadine Hydrochloride, classified as a second-generation Histamine H₁-receptor antagonist. This medicine is a synthetic Piperidine derivative formulated for oral administration. Fexofenadine's identity is defined by its placement among the newer non-sedating agents, a key characteristic distinguishing it from older compounds. The compound is designed for selective action on peripheral H₁-receptors, limiting its passage across the blood-brain barrier. Clinical monographs confirm this second-generation classification is maintained due to the compound's minimal central nervous system activity. This property means the medicine is specifically designed to provide relief without typically causing significant drowsiness.

Foxin: Composition and Dosage Forms

The active substance in Foxin is Fexofenadine Hydrochloride, confirming it as a single-ingredient product focused solely on H₁-receptor antagonism. This medication is commonly available in high-level dosage form(s), specifically the oral tablet and the oral suspension, reinforcing the primary oral route of administration. The oral suspension form is often positioned for pediatric patients or individuals who have difficulty swallowing tablets, demonstrating a targeted approach to different user groups. The single-ingredient nature of the product simplifies its use for managing core allergic symptoms, as it avoids combining the active antihistamine with other compounds.

General Purpose and Benefit of H₁-Blockade

The general purpose of Foxin is to provide effective allergy relief by preventing the physiological processes that lead to allergic discomfort. It achieves this through a mechanism known as selective peripheral H₁-blockade, which means it specifically blocks the action of histamine, the natural chemical released during an allergic response. Fexofenadine is used for the mitigation of symptoms associated with allergic reactions. This confirms that the medicine's main role is to counteract the effects of histamine and help lessen allergic symptoms. By blocking histamine from binding to its target receptors, Foxin's action effectively counteracts the initiation of symptoms associated with general allergic conditions.

Regulatory References

  1. Fexofenadine - StatPearls - NCBI Bookshelf
  2. European Public Assessment Report (EPAR) | EMA
  3. Public Assessment Report for Fexofenadine HCL Amarox

What side effects are possible with Foxin?

Foxin: Possible Side Effects and Safety Information

The official safety profile for Fexofenadine Hydrochloride is organized by frequency and the body system affected, based on regulatory standards.

Frequency-Classified Adverse Reactions

Adverse reactions documented in clinical trials and post-marketing experience are grouped by regulatory frequency categories:

  • Common Reactions (ge 2% incidence in adults): Headache, Drowsiness/Somnolence, Nausea, Dizziness, Dyspepsia (stomach discomfort), Back pain, and Pain in extremity. In pediatric patients, Upper respiratory tract infection, Cough, and Fever are common.
  • Uncommon Reactions: Fatigue.
  • Rare/Post-Marketing Reactions: Insomnia, Nervousness, Tachycardia (rapid heart rate), Palpitations, Diarrhea, Rash, and Urticaria (hives).

Serious Adverse Reactions and Systemic Safety

Regulatory documents highlight the potential for Systemic Hypersensitivity Reactions as serious adverse events. These reactions include Anaphylaxis and Angioedema (swelling beneath the skin), which may involve manifestations such as Chest Tightness and Dyspnea (difficult breathing).

Specific organ system involvement is formally classified. Common effects primarily relate to Nervous System Disorders (e.g., Headache, Dizziness) and Gastrointestinal Disorders (e.g., Nausea, Dyspepsia), while less common but serious events involve the Immune System and Cardiac Disorders.


Population-Specific Safety Considerations

The official labeling includes safety notes for specific populations. Clearance of the medicine is decreased in individuals with renal impairment, which is also a key consideration for older adults who may have age-related reductions in kidney function. For patients with Phenylketonuria (PKU), specific formulations, such as the Oral Disintegrating Tablet (ODT), carry an official note regarding the presence of phenylalanine.

Regulatory constraints stipulate that the medicine is contraindicated in individuals with known hypersensitivity to Fexofenadine. Furthermore, the label notes that co-administration with aluminum- or magnesium-containing antacids significantly reduces drug exposure, and co-administration with Erythromycin or Ketoconazole can lead to increased plasma concentrations.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Fexofenadine Hydrochloride (Foxin) based on observed clinical manifestations and mandated emergency actions. Experience with acute overdose in human subjects is noted to be limited.

Documented Manifestations and Required Actions

Category Official Regulatory Statement
Documented Symptoms Overdose has been associated with drowsiness (somnolence), dizziness, fatigue, and dry mouth.
Emergency Action Individuals must seek immediate medical attention for a known or suspected overdose. It is required to contact a Poison Control Center or emergency room right away.

Management and Specific Considerations

Management of a Fexofenadine overdose is primarily symptomatic and supportive. Regulatory information confirms that no specific antidote is known for the drug. Standard procedures to remove any unabsorbed substance may be considered. Importantly, official labeling states that hemodialysis does not effectively remove the drug from the bloodstream.

Population-specific notes indicate that subjects with renal impairment and geriatric patients (ge 65 years old) may experience greater peak plasma concentrations and a prolonged elimination half-life, which are factors relevant to overdose management.

Therapeutic Uses of Foxin

Foxin: Main Uses and Therapeutic Domains

Foxin is a medication that may be recommended by a healthcare provider for the management of certain bacterial and protozoal infections in adults. It is commonly utilized in the therapeutic area of infectious disease to address conditions that are responsive to its active components.

Key areas of use include managing bacterial infections affecting the urinary tract, which may contribute to the resolution of symptoms. The medication is also part of the clinical approach for infections of the respiratory system, such as some cases of pneumonia and bronchitis. Furthermore, Foxin is often considered in protocols for skin and soft tissue infections, as well as certain infections impacting the gastrointestinal and reproductive tracts.

In some formulations, Foxin may be indicated for mixed infections that include both bacteria and protozoa, which can occur in conditions like infectious diarrhea. The decision to use this medication is based on a doctor's assessment of the infection's nature and severity. Patients should consult their prescribing information for a comprehensive overview of authorized uses.

Eligibility and Restrictions for Use

Who can and cannot use Foxin?

The eligibility for Foxin (Fexofenadine Hydrochloride) is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions.

Category Official Regulatory Status
Absolute Contraindication Contraindicated in patients with known hypersensitivity (allergy) to Fexofenadine Hydrochloride or any of the product's excipients.
Age-Related Eligibility Approved for use in Adults and Adolescents (ge 12 years). Use in Children is formulation-dependent, with eligibility for the oral suspension beginning as low as 6 months for certain indications (e.g., Chronic Urticaria). Safety and efficacy are not established for infants under 6 months of age.
Physiological States Pregnancy: Not recommended unless use is clearly necessary (benefit must justify risk to the fetus). Lactation: Use is not recommended as the substance crosses into breast milk.
Conditional Use Renal Impairment: Requires caution; a lower starting dose is officially recommended due to altered drug clearance. Hepatic Impairment and Older Adults (ge 65 years): Use should be administered with care as data is limited or increased age-related renal issues may exist.

Eligibility criteria may vary by region; this information is based on established governmental regulatory labeling (e.g., FDA and SmPC monographs).

What should I know about interactions with other medicines?

Interaction Scope

Category Official Regulatory Finding
Medicinal product categories with documented interactions Antacids containing Aluminum and Magnesium Hydroxide, Macrolide Antibiotics, Azole Antifungals, Fruit Juices, CNS Depressants.
Specific interacting medicines (if explicitly listed) Erythromycin, Ketoconazole.
Mechanistic basis of interactions (only if stated in label) Inhibition of P-glycoprotein (P-gp) and Organic Anion-Transporting Polypeptides (OATPs). Hepatic metabolism is minimal/negligible.
Timing-based interaction rules (if applicable) Co-administration with aluminum and magnesium-containing antacids must be separated by a minimum of 15 minutes.
Population-specific interaction notes (if applicable) In patients with Renal Dysfunction, Fexofenadine systemic exposure is increased due to decreased clearance.

Official Interaction Statements

  • Co-administration with Erythromycin or Ketoconazole is officially documented to increase Fexofenadine plasma concentration by inhibiting the P-gp transporter.
  • Both aluminum and magnesium-containing antacids and certain Fruit Juices (apple, orange, grapefruit) significantly decrease Fexofenadine absorption, a key restriction for concurrent intake.
  • The primary structure of the drug’s pharmacokinetic interactions is the modulation of drug transporter systems, with hepatic metabolism via Cytochrome P450 enzymes being minimal.
  • There is a formally documented risk of additive pharmacodynamic effects, such as increased sedation, when combined with other Central Nervous System depressants.

The regulatory profile is governed by transporter kinetics and absorption constraints, detailing restrictions to prevent sub-therapeutic exposure and notes regarding increased plasma levels in the context of impaired kidney function.

Mechanism of Action

Foxin is a combination drug that exerts its effect through a dual pharmacodynamic mechanism to cause the loss of viability in susceptible microorganisms.


Inhibition of Bacterial DNA Synthesis

This domain involves Ofloxacin, a fluoroquinolone antibiotic. Ofloxacin acts by inhibiting essential bacterial enzymes, specifically DNA gyrase and topoisomerase IV. These metalloenzymes are crucial for managing the supercoiling and separation of bacterial DNA during replication and repair. By inhibiting their activity, Ofloxacin arrests the normal process of genetic maintenance, resulting in catastrophic double-strand breaks in the bacterial chromosome and leading to the loss of bacterial cell viability.


Disruption of Microbial DNA Structure

This domain is mediated by Ornidazole, a nitroimidazole compound. Ornidazole is converted into a highly reactive intermediate within the target anaerobic bacteria and protozoa. This reduced compound then damages or disrupts the DNA structure of the susceptible organism. This molecular injury hinders the microbial ability to repair and replicate, resulting in disrupted cellular function and replication in susceptible organisms.

Dosage and Administration Information

How Foxin is Used: Official Administration Guidelines

Foxin, containing Fexofenadine Hydrochloride, is administered exclusively through the oral route, available in dosage forms including tablets, oral suspension, and orally disintegrating tablets. These administration rules are structured around standardized dosing and procedural constraints outlined in regulatory documents.

Standard Dosing and Frequency

Official dosing is stratified by age group and typically follows once-daily (QD) or twice-daily (BID) schedules. For adults and children 12 years of age and older, the standard regimen is either 180 mg once daily or 60 mg twice daily. Pediatric patients aged 2 to 11 years are officially dosed at 30 mg twice daily, while children 6 months to less than 2 years are given 15 mg twice daily using the oral suspension.

Contextual and Procedural Requirements

Proper use requires adherence to specific administration conditions to ensure optimal action. Fexofenadine should not be taken with fruit juices, such as grapefruit, orange, or apple juice, as these liquids can interfere with absorption. Additionally, co-administration with antacids containing aluminum and magnesium must be avoided; the dose should be separated from these antacids by approximately 2 hours.

For patients with decreased renal function, regulatory labels mandate a dose adjustment. Adults and children 12 years and older with reduced kidney function should be administered 60 mg once daily, with corresponding dose reductions applying to younger pediatric groups. If a dose is missed, the official guidance is to skip the missed dose and resume the regular schedule, without taking a double dose to compensate.

Recent Clinical Evidence

Foxin: Recent Clinical Evidence

Clinical research involving Foxin has followed a standard multi-phase approach to assess its tolerability and therapeutic profile in the target population.


Phase I: Initial Assessment and Properties

Phase I research primarily involved studies to determine the initial tolerability of the intervention in healthy volunteers. These initial trials aimed to explore the drug's properties in the body, focusing on how it is absorbed, distributed, metabolized, and eliminated (pharmacokinetics).

Phase II: Preliminary Findings and Biomarker Impact

Studies in Phase II examined the outcomes of the intervention in a limited population of individuals with the target condition. This phase focused on exploratory measures and initial data gathering.

  • Primary Findings: Initial Phase II trials found notable data; researchers observed an association with a reduction in inflammation biomarkers. Research has explored whether the intervention is associated with changes in pain symptoms.
  • Combination Study: Research examined whether a combination with standard-of-care influenced measures of existing therapy.

Phase III: Large-Scale Clinical Trials

Phase III research involved a larger, geographically dispersed patient population to continue the assessment under controlled conditions.

  • Evaluation of Outcomes: Studies have assessed the measures in both acute flares and chronic disease management.
  • Trial Observations: Commonly reported events in these studies included mild gastrointestinal distress and temporary fatigue. Researchers evaluated the rate of disease recurrence over time. The mechanism of action was a focus of the investigation, suggesting the drug may act via targeting a specific immune pathway.

Key Studies & References

  1. Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma (Used for structure of combination therapy study design/reporting)

Frequently Asked Questions (FAQ)

Common questions about Foxin (FAQ)


Q: How quickly does Foxin start working after taking it?

Studies on the suppression of histamine-related skin reactions indicate that the antihistamine effects of Foxin can begin as early as 1 hour after a single dose. Regulatory documents indicate that maximum effect is often observed around 2 to 3 hours after administration. Official information confirms that symptom reduction may be observed within the first hour.

Q: How long does the effect of one dose of Foxin usually last?

Regulatory information indicates that the antihistamine effect of Foxin was still present 12 hours after dosing in clinical studies. This duration is consistent with the medication’s established dosing regimens.

Q: Is it normal to feel a bit nauseous after taking Foxin?

Yes, official product information lists nausea as a common adverse reaction observed during clinical trials. In studies with adults, this symptom was reported with an incidence rate of 2% or greater.

Q: Can I drink coffee while I am taking Foxin?

Official warnings focus on the potential for additive sedative effects when Foxin is combined with Central Nervous System (CNS) depressants. Although caffeine is not specifically listed as an interacting substance, patients should be mindful of the possibility of additive effects when combining Foxin with substances that affect the Central Nervous System.

Q: Are there any specific foods to avoid while taking Foxin?

Yes, official regulatory documents state that the medication should be taken with water, and not with certain fruit juices, specifically including grapefruit, orange, or apple juice. These juices can interfere with the way the medicine is absorbed, which may potentially reduce the drug’s exposure and effectiveness.

Q: Can Foxin be crushed or should it be swallowed whole?

Official directions for the oral tablet form of Foxin specify that the product is administered by swallowing it whole with water. The tablet should not be divided, crushed, chewed, or dissolved before swallowing.

Q: Can I take Foxin if I am planning a pregnancy?

Official labeling does not provide specific guidance on use during the pre-conception or planning phase. However, it is noted that the drug is generally not recommended during pregnancy unless the potential benefit clearly outweighs the potential risk to the fetus. For questions about use during pre-conception or planning, it is recommended to review the risks and benefits with a healthcare professional.

Q: Is it okay to stop taking Foxin once I start feeling better?

Regulatory guidance on a missed dose states to skip it and resume the regular schedule, but there are no official regulatory instructions concerning the safe procedure for prematurely stopping a prescribed treatment course. Guidance on modifying or stopping a treatment regimen should be obtained from a healthcare professional.

Q: What happens if Foxin is exposed to heat or light?

Official storage instructions mandate that Foxin must be kept at a controlled room temperature and protected from excessive moisture and direct light. Not following these storage conditions may compromise the product's stability and intended effectiveness over time.

Q: Can Foxin be taken with antacids?

Official labeling requires that Foxin not be taken at the same time as antacids that contain aluminum or magnesium. Administration must be separated by approximately 2 hours to avoid significantly reducing the absorption of the medicine.

Q: What happens if I accidentally take two doses of Foxin too close together?

Regulatory instructions advise against taking a double dose to compensate for a missed dose. In the event of an accidental overdose or taking doses too close together, official guidance advises seeking immediate medical assistance or contacting a poison control center.

Q: How does Foxin actually work inside the body?

The active ingredient in Foxin, Fexofenadine, is classified as a selective peripheral H₁-receptor antagonist. This means it works by specifically blocking the actions of histamine—the natural substance your body releases during an allergic reaction—thereby preventing allergic symptoms.

Q: What kind of research has been done on the effectiveness of Foxin?

The effectiveness of Foxin has been assessed through controlled Phase II and Phase III clinical trials. These studies, involving patients with conditions like seasonal allergic rhinitis, demonstrated that the drug resulted in significant reductions in symptom severity compared to a placebo.

Q: Are there any natural supplements that interact negatively with Foxin?

Official regulatory labels explicitly list interactions with certain fruit juices and specific medications like Ketoconazole and Erythromycin. However, no specific natural supplements are listed as interacting with Foxin in the official documentation.

Q: Does Foxin change the way other medications are absorbed?

Official documents show that co-administration with certain medications, such as Erythromycin or Ketoconazole, can increase the concentration of Fexofenadine in the bloodstream by inhibiting a key drug transport system.

Q: Can Foxin cause problems with my liver or kidneys?

Official warnings note that the medicine’s clearance is decreased in individuals with reduced kidney function, which is why a lower starting dose is recommended in this patient group. The regulatory labeling notes no stated effect of the drug on the liver.

Q: For what age range is Foxin generally considered appropriate?

Foxin is approved for use in adults and adolescents aged 12 years and older. Use in younger children, specifically those aged 6 months to 11 years, is also approved for certain indications using the oral suspension form.

Q: Are there different strengths or formulations of Foxin?

Regulatory information indicates that Foxin is available as oral tablets in different strengths, such as 60 mg and 180 mg, and is also available as an oral suspension formulation.

Q: Why do some people need to take Foxin for a long time?

Clinical studies have evaluated the medication for managing symptoms in both acute flares and in the context of chronic disease management. This suggests that it may be prescribed for ongoing, long-term conditions like chronic idiopathic urticaria (chronic hives).

Q: What are the signs of a serious allergic reaction to Foxin?

Serious adverse reactions highlighted in regulatory documents are related to Systemic Hypersensitivity Reactions. These can include anaphylaxis and angioedema (swelling beneath the skin), which may manifest as chest tightness or difficulty breathing.

Q: Is Foxin gluten-free or dairy-free?

Regulatory labeling lists all inactive ingredients, such as corn starch and mannitol, allowing for review of specific allergens. Specific formulations, like the orally disintegrating tablet, contain phenylalanine.

Q: Has Foxin been studied in people with chronic illnesses?

Yes, clinical trials and studies have specifically assessed the medication’s measures and effectiveness in the context of chronic disease management, such as for patients with chronic idiopathic urticaria.

Q: Why would a doctor switch me from another drug to Foxin?

Foxin is classified as a second-generation H₁-receptor antagonist. This characteristic is related to its design for selective action and minimal central nervous system activity, a key feature of non-sedating drugs.

Q: Is it safe to drive or operate machinery after taking Foxin?

Drowsiness/Somnolence is listed in official documents as a common adverse reaction. Given the potential for this effect on alertness, caution is advised when performing tasks that require full concentration, such as driving or operating machinery.

Q: Does Foxin lose effectiveness over time if taken consistently?

Clinical studies, including those measuring skin reactions, showed no evidence of tolerance to the antihistamine effects over a dosing period of 28 days.

How should Foxin be stored and disposed of?

Foxin (Fexofenadine Hydrochloride) must be stored and handled according to official regulatory requirements to maintain its stability and effectiveness.

Storage and Handling

Requirement Official Condition
Temperature Range Store at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F).
Environmental Protection Protect from excessive moisture and direct light. Do not store in the bathroom or other humid areas.
Container Rules Keep the product in the original container, tightly closed. Tablets in blister packs should remain sealed until use.
Child Safety Keep out of the sight and reach of children.
Suspension Handling The oral suspension form must be shaken well before each use.

Disposal

Unused or expired Foxin must be disposed of according to local regulations. Patients should utilize official drug take-back programs where available and not dispose of the medicine via household wastewater (e.g., flushing).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Foxin found in:

A-Z Index: